Deutsche Bank Aktiengesellschaft Cuts Spire Healthcare Group (LON:SPI) Price Target to GBX 300

Spire Healthcare Group (LON:SPI) had its target price lowered by Deutsche Bank Aktiengesellschaft from GBX 320 ($4.13) to GBX 300 ($3.88) in a report published on Thursday morning, Marketbeat reports. The brokerage currently has a buy rating on the stock.

Spire Healthcare Group Trading Down 6.0 %

LON:SPI opened at GBX 177.20 ($2.29) on Thursday. Spire Healthcare Group has a one year low of GBX 168.20 ($2.17) and a one year high of GBX 270.50 ($3.50). The company has a debt-to-equity ratio of 62.25, a current ratio of 0.70 and a quick ratio of 0.74. The firm has a market capitalization of £711.58 million, a price-to-earnings ratio of 25.22, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96. The business has a fifty day moving average price of GBX 227.28 and a 200-day moving average price of GBX 229.56.

Spire Healthcare Group (LON:SPI) last issued its quarterly earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share (EPS) for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. Sell-side analysts forecast that Spire Healthcare Group will post 15.6634747 EPS for the current year.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.